Skip to main content
Top
Published in: Neurological Sciences 1/2011

01-05-2011 | Closing Lecture

Oral contraceptives in migraine therapy

Authors: Gianni Allais, Ilaria Castagnoli Gabellari, Cristina De Lorenzo, Ornella Mana, Chiara Benedetto

Published in: Neurological Sciences | Special Issue 1/2011

Login to get access

Abstract

Even if sometimes combined oral contraceptives (COCs) can initiate or aggravate headaches, in particular migraine, the headaches generally tend to improve after the first months of COC use. If migraine persists, in many patients the attacks are more likely to occur during the pill-free week, and an oral contraceptive-induced menstrual migraine (OCMM) occurs. In case of OCMM, some hormonal manipulations are available, by eliminating or reducing the hormone-free interval (HFI), in order to prevent this estrogen-withdrawal headache. It is possible to use a continuous COCs regimen, to shorten the HFI to less than the traditional 7 days, to use a low-dose estrogen supplementation after the 21 days of COCs or to prescribe a progestogen–only pill (POP). Interestingly, the use of a POP is a safe option also for women suffering from migraine with aura (in which COCs are absolutely contraindicated) and a recent trial suggests that its use can reduce the frequency of migraine attacks and the duration of aura symptoms too.
Literature
1.
go back to reference Burkman RT, Collins JA, Shulman LP, Williams JK (2001) Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185:S4–S12PubMedCrossRef Burkman RT, Collins JA, Shulman LP, Williams JK (2001) Current perspectives on oral contraceptive use. Am J Obstet Gynecol 185:S4–S12PubMedCrossRef
2.
go back to reference MacGregor EA, de Lignières B (2000) The place of combined oral contraceptives in contraception. Cephalalgia 20:157–163PubMedCrossRef MacGregor EA, de Lignières B (2000) The place of combined oral contraceptives in contraception. Cephalalgia 20:157–163PubMedCrossRef
3.
go back to reference Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193:636–649PubMedCrossRef Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193:636–649PubMedCrossRef
4.
go back to reference Mueller L (2000) Predictability of exogenous hormone effect in subgroups of migraineurs. Headache 40:189–193PubMedCrossRef Mueller L (2000) Predictability of exogenous hormone effect in subgroups of migraineurs. Headache 40:189–193PubMedCrossRef
5.
go back to reference MacGregor EA, Igarashi H, Wilkinson M (1997) Headaches and hormones: subjective versus objective assessment. Headache Q 8:126–136 MacGregor EA, Igarashi H, Wilkinson M (1997) Headaches and hormones: subjective versus objective assessment. Headache Q 8:126–136
6.
go back to reference Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M (1995) Sex-hormone related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15:140–144PubMedCrossRef Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M (1995) Sex-hormone related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15:140–144PubMedCrossRef
7.
go back to reference Granella F, Sances G, Zanferrari C, Costa A, Martignoni GC (1993) Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33:385–389PubMedCrossRef Granella F, Sances G, Zanferrari C, Costa A, Martignoni GC (1993) Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 33:385–389PubMedCrossRef
8.
go back to reference Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgi 20:170–174CrossRef Massiou H, MacGregor EA (2000) Evolution and treatment of migraine with oral contraceptives. Cephalalgi 20:170–174CrossRef
9.
go back to reference MacGregor EA, Hackshaw A (2002) Prevention of migraine in the pill-free week of combined oral contraceptives using natural oestrogen supplements. J Fam Plann Reprod Health Care 28(1):27–31PubMedCrossRef MacGregor EA, Hackshaw A (2002) Prevention of migraine in the pill-free week of combined oral contraceptives using natural oestrogen supplements. J Fam Plann Reprod Health Care 28(1):27–31PubMedCrossRef
10.
go back to reference Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ (2000) Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95:261–266PubMedCrossRef Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ (2000) Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 95:261–266PubMedCrossRef
11.
go back to reference Sulak P, Willis S, Kuehl T, Coffee A, Clark J (2007) Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47:27–37PubMed Sulak P, Willis S, Kuehl T, Coffee A, Clark J (2007) Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47:27–37PubMed
12.
go back to reference Allais G, Bussone G, Airola G, Borgogno P, Castagnoli Gabellari I, de Lorenzo C, Pavia E, Benedetto C (2008) Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 29(Suppl 1):S186–S190PubMedCrossRef Allais G, Bussone G, Airola G, Borgogno P, Castagnoli Gabellari I, de Lorenzo C, Pavia E, Benedetto C (2008) Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 29(Suppl 1):S186–S190PubMedCrossRef
13.
go back to reference MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67:2154–2158PubMedCrossRef MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67:2154–2158PubMedCrossRef
15.
16.
go back to reference Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24(Suppl.1):1–160 Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24(Suppl.1):1–160
17.
go back to reference Sulak PJ, Kuehl TJ, Ortiz M, Shull BL (2002) Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186:1142–1149PubMedCrossRef Sulak PJ, Kuehl TJ, Ortiz M, Shull BL (2002) Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186:1142–1149PubMedCrossRef
18.
go back to reference Sulak PJ (2008) Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol 22(2):355–374PubMedCrossRef Sulak PJ (2008) Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol 22(2):355–374PubMedCrossRef
19.
go back to reference Klipping D, Duijkers I, Trummer D, Marr J (2008) Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78(1):16–25PubMedCrossRef Klipping D, Duijkers I, Trummer D, Marr J (2008) Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78(1):16–25PubMedCrossRef
20.
go back to reference Sullivan H, Furniss H, Spona J, Elstein M (1999) Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 72(1):115–120PubMedCrossRef Sullivan H, Furniss H, Spona J, Elstein M (1999) Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril 72(1):115–120PubMedCrossRef
21.
go back to reference Nakajima ST, Archer DF, Ellman H (2007) Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin® 24 Fe). Contraception 75:16–22PubMedCrossRef Nakajima ST, Archer DF, Ellman H (2007) Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 μg (Loestrin® 24 Fe). Contraception 75:16–22PubMedCrossRef
22.
go back to reference Poindexter A, Reape KZ, Hait H (2008) Efficacy and safety of a 28-day oral contraceptive with 7 days of low dose estrogen in place of placebo. Contraception 78:113–119PubMedCrossRef Poindexter A, Reape KZ, Hait H (2008) Efficacy and safety of a 28-day oral contraceptive with 7 days of low dose estrogen in place of placebo. Contraception 78:113–119PubMedCrossRef
23.
go back to reference Rice CF, Killick SR, Dieben T, Coelingh Bennink H (1999) A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 14:982–985PubMedCrossRef Rice CF, Killick SR, Dieben T, Coelingh Bennink H (1999) A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 14:982–985PubMedCrossRef
24.
go back to reference Grimes DA, Lopez LM, O’Brien PA, Raymond EG (2010) Progestin-only pills for contraception. Cochrane Database Syst Rev (1):CD007541 Grimes DA, Lopez LM, O’Brien PA, Raymond EG (2010) Progestin-only pills for contraception. Cochrane Database Syst Rev (1):CD007541
25.
go back to reference Ahrendt HJ, Karckt U, Pichl T, Mueller T, Ernst U (2007) The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results form two studies on oestrogen-related symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care 12:354–361PubMedCrossRef Ahrendt HJ, Karckt U, Pichl T, Mueller T, Ernst U (2007) The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results form two studies on oestrogen-related symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care 12:354–361PubMedCrossRef
26.
go back to reference Ahrendt HJ, Kleinschmidt S, Kropf S et al (2007) Präventive Wirkung hormoneller Kontrazeptiva im Langzyklus bei menstrueller Migräne. Frauenarzt 48:2–7 Ahrendt HJ, Kleinschmidt S, Kropf S et al (2007) Präventive Wirkung hormoneller Kontrazeptiva im Langzyklus bei menstrueller Migräne. Frauenarzt 48:2–7
27.
go back to reference World Health Organization (2004) Family and Reproductive Health Programme. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use, 3rd edn. World Health Organization Geneva, Switzerland World Health Organization (2004) Family and Reproductive Health Programme. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use, 3rd edn. World Health Organization Geneva, Switzerland
28.
go back to reference ACOG Committee on Practice Bulletins-Gynecology (2006) ACOG practice bulletin. No73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107:1453–1472CrossRef ACOG Committee on Practice Bulletins-Gynecology (2006) ACOG practice bulletin. No73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107:1453–1472CrossRef
30.
go back to reference Nappi EW, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, Polatti F, Facchinetti F (2011) Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception 83(3):223–228PubMedCrossRef Nappi EW, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, Polatti F, Facchinetti F (2011) Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception 83(3):223–228PubMedCrossRef
Metadata
Title
Oral contraceptives in migraine therapy
Authors
Gianni Allais
Ilaria Castagnoli Gabellari
Cristina De Lorenzo
Ornella Mana
Chiara Benedetto
Publication date
01-05-2011
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2011
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-011-0538-z

Other articles of this Special Issue 1/2011

Neurological Sciences 1/2011 Go to the issue